{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:02:22Z","timestamp":1787241742678,"version":"build-2736575974"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100020193","name":"Novartis Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020193","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monoclonal antibodies that target the CD20 antigen and cause B-cell depletion have proven to be a highly effective treatment strategy in relapsing-remitting MS (RRMS). Ofatumumab, the first fully human anti-CD20 monoclonal antibody, was approved for RRMS treatment in 2021 following successful phase III clinical trials. Real-world patient populations are inherently heterogeneous and offer further insights into the impact of therapies on disease activity, adverse events and immunological parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and effectiveness of ofatumumab in a clinic-based MS population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult RRMS patients attending a clinic in Sydney, Australia, treated with ofatumumab were included. A retrospective review of medical records was undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 170 patients were enrolled. Mean age was 46.2 years (\u00b111.0). Median duration of treatment with ofatumumab was 18.1 months (11.0\u201326.0). 96.5% of patients met three-parameter criteria for no evidence of disease activity (NEDA-3) during treatment. No relapses occurred. Eighteen patients had progression independent of relapse activity (PIRA) in the 12 months before ofatumumab, 12 of whom stabilised. Serious infections occurred in 2.9%, and 6.4% stopped treatment due to adverse events. Immunoglobulin levels decreased on treatment, though this was only significant for IgM (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001) and lower levels were not associated with infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates high effectiveness of ofatumumab in an older RRMS population with longer disease duration than pivotal trials. A positive effect on PIRA was observed in 66.7% of those experiencing it in the year prior. Discontinuation due to adverse events was rare.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173251414528","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:24:13Z","timestamp":1771867453000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-1756","authenticated-orcid":false,"given":"Turlough","family":"Montague","sequence":"first","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Cheung","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Kang","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesha","family":"Venkatesha","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Zeme","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Ferrier","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Thomas","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Simpson-Burke","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Miller","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chatterton","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Fontes Villalba","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp14X682609"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04143.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.05.003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231213230"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12010119"},{"key":"e_1_3_2_10_2","volume-title":"Utilisation of high efficacy therapy for managing multiple sclerosis in Australia [poster]Presented at: Australian and New Zealand Association of Neurologists (ANZAN) annual scientific meeting","author":"McCombe P","unstructured":"McCombe P, Butzkueven H, Samjoo I, et al. Utilisation of high efficacy therapy for managing multiple sclerosis in Australia [poster]. In: Presented at: Australian and New Zealand Association of Neurologists (ANZAN) annual scientific meeting, Brisbane, Australia, May 2025."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1521726"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211109"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104881"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104701"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009"},{"key":"e_1_3_2_16_2","unstructured":"Department of Health and Aged Care. Pharmaceutical Benefits Scheme\u00a0(PBS) | Ofatumumab \u2013 Item 12642J. Canberra (AU): Australian Government; [cited 2025 Jun 30] https:\/\/www.pbs.gov.au\/medicine\/item\/12642J."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww173"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12448-4"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12360-x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106425"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00456-6"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173251414528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173251414528","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173251414528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:02:00Z","timestamp":1773226920000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173251414528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/20552173251414528"],"URL":"https:\/\/doi.org\/10.1177\/20552173251414528","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"20552173251414528"}}